Výsledky vyhledávání

Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline

Autor: Jonathan Poirier, Sophie Godemel, Aurélie Mourot, Solange Grunenwald, Harold J Olney, Xuan Kim Le, André Lacroix, Philippe Caron, Isabelle Bourdeau

Publikováno v: The Journal of Clinical Endocrinology & Metabolism.

ContextCentral hypothyroidism was described previously in mitotane-treated patients but data on its prevalence and time of occurrence are limited.ObjectiveTo better characterize thyroid hormone insufficiency in patients exposed to mitotane.MethodsWe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3f54b8343111861fc6d32761eaaa2d0a
https://doi.org/10.1210/clinem/dgad115

Zobrazit plný text záznamu

Central hypothyroidism is frequent during mitotane therapy in adrenocortical cancer (ACC) patients: Prevalence and timeline

Autor: Jonathan Poirier, Sophie Godemel, Aurélie Mourot, Solange Grunenwal, Harold J. Olney, Xuan Kim Le, André Lacroix, Philippe Caron, Isabelle Bourdeau

Publikováno v: Annales d'Endocrinologie. 84:331

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::435ed292ff5c7cdf213a962ac406a4a9
https://doi.org/10.1016/j.ando.2023.03.020

Zobrazit plný text záznamu

Postoperative Recurrences in Patients Operated for Pheochromocytomas and Paragangliomas: New Data Supporting Lifelong Surveillance

Autor: Stefanie Parisien-La Salle, Jessica Chbat, André Lacroix, Paul Perrotte, Pierre Karakiewicz, Issam Saliba, Xuan Kim Le, Harold J. Olney, Isabelle Bourdeau

Publikováno v: Cancers; Volume 14; Issue 12; Pages: 2942

At least 10% of pheochromocytomas (PHEOs) and paragangliomas (PGLs) (PPGLs) may recur after the initial surgery. Guidelines recommend annual screening for recurrence in non-metastatic tumors for at least 10 years after the initial surgical resection

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11eb6eefd9d8276aa1e3aaa2df005e81
https://pubmed.ncbi.nlm.nih.gov/35740606

Zobrazit plný text záznamu

Plný text ve formátu HTML

Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects

Autor: Sarah Hamidi, Andrée Boucher, Bernard Lemieux, Geneviève Rondeau, Rebecca Lebœuf, Louis-Georges Ste-Marie, Xuan Kim Le, Hortensia Mircescu

Publikováno v: Journal of the Endocrine Society. 6(6)

Context The SELECT trial led to the approval of lenvatinib for the treatment of advanced radioiodine-refractory differentiated thyroid carcinomas (DTCs) but also revealed an important adverse event (AE) profile which may limit its use in clinical pra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c8d26bc9f4fb451197689a68530fe74
https://pubmed.ncbi.nlm.nih.gov/35475024

Zobrazit plný text záznamu

SAT-169 Adrenocortical Cancer Is Diagnosed at Large Size and Advanced Stage in a Canadian Referral Center; Focus on Modes of Presentation Depending on Stages

Autor: Harold J. Olney, Jonathan Poirier, Mathieu Latour, André Lacroix, Pierre I. Karakiewicz, Catherine Alguire, Xuan Kim Le, Isabelle Bourdeau, Nadia Gagnon, Paul Perrotte

Publikováno v: Journal of the Endocrine Society

Context: Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 0.7-2 per million. Based on the ENSAT staging classification, tumor stage is the most important prognostic factor; the presence of lymph nodes involvement and metastases is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53905a097a5ad839dd123c6ea5a28044
https://doi.org/10.1210/jendso/bvaa046.1578

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání